{"gene":"THAP1","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2005,"finding":"The THAP domain of THAP1 is a zinc-dependent sequence-specific DNA-binding domain belonging to the zinc-finger superfamily. In vitro binding-site selection identified an 11-nucleotide consensus DNA-binding sequence recognized by the THAP domain. Site-directed mutagenesis of the C2CH motif cysteines and histidine abolished DNA binding, and zinc chelation with 1,10-o-phenanthroline confirmed zinc dependency. Four conserved residues (P, W, F, P) were also required for DNA binding.","method":"In vitro binding-site selection (SELEX), site-directed mutagenesis, zinc chelation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding with mutagenesis of multiple residues confirming mechanism","pmids":["15863623"],"is_preprint":false},{"year":2003,"finding":"THAP1 localizes to PML nuclear bodies and interacts with the proapoptotic protein Par-4. THAP1 potentiates serum withdrawal- and TNF-alpha-induced apoptosis. The THAP domain is not required for Par-4 binding or PML NB localization but is essential for THAP1 proapoptotic activity.","method":"Subcellular localization by immunofluorescence, Co-immunoprecipitation, functional apoptosis assays, domain deletion analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — reciprocal localization studies with domain mutagenesis and functional readout","pmids":["12717420"],"is_preprint":false},{"year":2006,"finding":"THAP1 regulates endothelial cell proliferation and G1/S cell-cycle progression by coordinated repression of pRB/E2F cell-cycle target genes. Chromatin immunoprecipitation showed endogenous THAP1 binds a consensus THAP1-binding site in the RRM1 promoter in vivo, establishing RRM1 as a direct transcriptional target. Both overexpression and RNAi silencing of THAP1 inhibit EC proliferation, indicating an optimal expression range is required.","method":"Retroviral gene transfer, RNA interference, microarray expression profiling, chromatin immunoprecipitation (ChIP)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, RNAi, OE) with defined cellular phenotype","pmids":["17003378"],"is_preprint":false},{"year":2007,"finding":"NMR structure of the THAP zinc finger of THAP1 revealed an atypical ~80-residue zinc finger with a short antiparallel beta-sheet and a long loop-helix-loop insertion between C2CH zinc-coordinating residues. Alanine scanning mutagenesis and NMR chemical shift perturbation mapped the DNA-binding interface to a highly positively charged surface with multiple lysine and arginine residues.","method":"Multidimensional NMR spectroscopy, deletion mutagenesis, alanine scanning mutagenesis, NMR chemical shift perturbation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — 3D structure determined by NMR with mutagenesis validation of DNA-binding residues","pmids":["18073205"],"is_preprint":false},{"year":2009,"finding":"A missense mutation in THAP1 found in DYT6 primary torsion dystonia families impairs DNA binding of the THAP domain, suggesting transcriptional dysregulation contributes to the disease phenotype.","method":"Genetic identification followed by DNA binding assay demonstrating functional impairment of mutant THAP1","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 — functional DNA-binding assay on disease mutation, single study","pmids":["19182804"],"is_preprint":false},{"year":2010,"finding":"THAP1 binds directly to the core promoter of TOR1A (DYT1) and represses its expression. Dystonia-6-associated mutant THAP1 shows decreased repression of TOR1A compared to wild-type. This was demonstrated by electrophoretic mobility shift assay (EMSA) and ChIP-qPCR.","method":"Electromobility shift assay (EMSA), chromatin immunoprecipitation quantitative PCR (ChIP-qPCR), luciferase reporter assays","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding demonstrated by EMSA and ChIP, replicated by two independent labs (PMID 20976771 and 20865765)","pmids":["20976771","20865765"],"is_preprint":false},{"year":2010,"finding":"THAP1 associates with the transcriptional coactivator HCF-1 and O-GlcNAc transferase (OGT) in vivo through a conserved HCF-1-binding motif (HBM). THAP1 mediates recruitment of HCF-1 to the RRM1 promoter during endothelial cell proliferation, and HCF-1 is essential for transcriptional activation of RRM1.","method":"Proteomic analysis (mass spectrometry), in vitro binding, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — MS-identified interaction confirmed by Co-IP and ChIP with functional RNAi validation","pmids":["20200153"],"is_preprint":false},{"year":2011,"finding":"THAP1 self-associates (dimerizes) through a region within its C-terminal coiled-coil domain, specifically residues 154–166 containing leucine-zipper-like elements. The DYT6 frameshift mutation Q154fs180X, which removes most of the coiled-coil domain, abolishes self-association, whereas other disease mutations within the coiled-coil (C54Y, F81L, ΔF132, T142A, I149T, A166T) do not disrupt dimerization.","method":"Co-immunoprecipitation, domain deletion and truncation analysis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 3 — single lab Co-IP with systematic mutant analysis","pmids":["21752024"],"is_preprint":false},{"year":2012,"finding":"NMR, fluorescence, DSF, and ITC analyses of DYT6 missense mutations within the THAP DNA-binding domain showed that mutations do not uniformly abolish DNA binding; some mutants bind DNA stronger than wild-type. However, some mutations alter DNA-binding specificity and most dramatically reduce protein thermostability (unfolding temperatures below 37°C for some mutants vs. 46°C for wild-type), suggesting reduced folded protein population under physiological conditions contributes to disease.","method":"NMR spectroscopy, fluorescence spectroscopy, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC)","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — multiple biophysical methods in one study examining mechanism of pathogenic mutations","pmids":["22844099"],"is_preprint":false},{"year":2014,"finding":"THAP1 autoregulates its own expression by binding to its own promoter and repressing transcription. Using luciferase reporter assays and quantitative ChIP, the THAP1 minimal promoter was mapped to a 480 bp fragment. DYT6-causing mutations disrupt this autoregulation, leading to elevated THAP1 levels. Overexpressed THAP1 is degraded via the proteasome.","method":"Luciferase reporter gene assays, quantitative ChIP, RT-qPCR, proteasome inhibitor experiments","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assays in single lab demonstrating feedback loop","pmids":["25088175"],"is_preprint":false},{"year":2013,"finding":"Par-4 and THAP1 form a protein complex through interaction of their carboxyl termini. THAP1 binds the CCAR1 promoter through its N-terminal zinc-dependent DNA-binding domain. The Par-4/THAP1 complex activates CCAR1 promoter and induces apoptosis. Additionally, Par-4/THAP1 and Notch3 competitively bind the CCAR1 promoter and competitively regulate alternative pre-mRNA splicing of CCAR1 via splicing factors SRp40 and SRp55.","method":"Co-immunoprecipitation, luciferase reporter assay, ChIP, splicing assay, domain deletion analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple methods but single lab; mechanistic detail on complex and splicing regulation","pmids":["23975424"],"is_preprint":false},{"year":2017,"finding":"THAP1 is essential for timing myelination initiation during CNS maturation through a cell-autonomous role in the oligodendrocyte (OL) lineage. Conditional deletion of THAP1 in the CNS retards OL maturation, delays myelination, and causes persistent motor deficits. Loss of THAP1 disrupts core OL maturation genes and reduces DNA occupancy of YY1, a transcription factor required for OL maturation.","method":"Conditional knockout mouse model, OL progenitor cell purification and developmental assays, ChIP for YY1","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with cell-autonomous rescue experiments and ChIP, replicated across multiple assays","pmids":["28697333"],"is_preprint":false},{"year":2017,"finding":"The coiled-coil domain of THAP1 spanning residues 139–185 is responsible for homodimerization, confirmed by yeast-two-hybrid, GST pull-down, and cross-linking assays. Nine reported DYT6-causing missense mutations within this region do not impair dimerization.","method":"Yeast-two-hybrid, GST pull-down, formaldehyde cross-linking assay","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — three orthogonal methods in single lab confirming dimerization domain","pmids":["28299530"],"is_preprint":false},{"year":2021,"finding":"THAP1 modulates extracellular matrix (ECM) composition in oligodendrocyte progenitor cells (OPCs) by regulating glycosaminoglycan (GAG) catabolism. THAP1 directly binds to and regulates the GusB gene encoding β-glucuronidase, a lysosomal GAG-catabolic enzyme. Loss of THAP1 causes OPCs to accumulate and secrete excess GAGs, inhibiting maturation through an autoinhibitory mechanism. Applying GAG-degrading enzymes or overexpressing β-glucuronidase rescues Thap1-/- OL maturation deficits in vitro and in vivo.","method":"ChIP, loss-of-function mouse model, rescue experiments with exogenous enzymes and viral overexpression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — direct target gene identified by ChIP, causal mechanism validated by rescue in vitro and in vivo","pmids":["34312226"],"is_preprint":false},{"year":2021,"finding":"THAP1, YY1, and HCF1 bind directly to the SHLD1 (Shieldin component) promoter and cooperatively maintain low basal expression of SHLD1, thereby controlling the balance between end protection and resection during DNA double-strand break repair. Loss of THAP1 alters SHLD1 expression and confers resistance to PARP inhibitors and cisplatin in BRCA1-deficient cells.","method":"ChIP, promoter binding assays, genetic epistasis in cell lines and mouse models, PARP inhibitor sensitivity assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct promoter binding, epistasis in multiple model systems, functional consequence on DSB repair","pmids":["33857404"],"is_preprint":false},{"year":2022,"finding":"The DYT6 missense mutation F81L (THAP1F81L) impairs THAP1 transcriptional activity and disrupts CNS myelination. THAP1F81L exhibits normal DNA binding but causes significantly reduced DNA binding of its transcriptional partner YY1, indicating that the mutation disrupts assembly of an active transcription complex rather than directly abolishing DNA binding.","method":"Knockin mouse model, ChIP for YY1 DNA occupancy, myelination assays, in vitro transcriptional activity assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — knockin model with ChIP showing loss of partner binding as mechanism, supported by functional myelination readout","pmids":["34686877"],"is_preprint":false},{"year":2022,"finding":"THAP1 mutations lead to dysregulation of genes mainly through regulation of SP1 family members SP1 and SP4 in a cell-type-dependent manner, as revealed by epigenomic and transcriptomic analyses in patient frontal cortex, iPSC-derived neurons, heterozygous knockout rat, and knockout cell lines. THAP1 directly targets only a minority of differentially expressed genes; broader transcriptional effects are mediated through SP1/SP4.","method":"ChIP-seq, RNA-seq in multiple model systems including patient tissue and iPSC-derived neurons","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq identifies indirect mechanism via SP1/SP4 across multiple model systems","pmids":["35015830"],"is_preprint":false},{"year":2025,"finding":"THAP1 directly regulates expression of PSMB5 (encoding proteasome subunit β5). Depletion of THAP1 disrupts proteasome assembly, reduces proteasome activity, and causes accumulation of ubiquitinated proteins. This was identified by genome-wide genetic screen and confirmed by ChIP demonstrating direct THAP1 binding to the PSMB5 promoter.","method":"Genome-wide genetic screen, ChIP, proteasome activity assays, ubiquitinated protein accumulation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide screen followed by ChIP confirmation and direct functional measurement, replicated in two independent studies (PMID 39952963 and 39929834)","pmids":["39952963","39929834"],"is_preprint":false},{"year":2025,"finding":"Deep mutational scanning of THAP1 systematically assessed the function of thousands of single amino acid variants, revealing that PSMB5 insufficiency from THAP1 loss leads to defective proteasome assembly and impaired proteostasis. RNA-seq defined THAP1 transcriptional targets, with PSMB5 as a critical direct target.","method":"Deep mutational scanning, RNA-seq, proteasome assembly assays, PSMB5 rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — deep mutational scan plus RNA-seq and functional rescue in a single rigorous study","pmids":["39929834"],"is_preprint":false},{"year":2020,"finding":"ChIP-seq showed THAP1 directly binds the promoter of SOD2 (superoxide dismutase 2). Overexpression of THAP1 increases SOD2 protein, while fibroblasts from THAP1 patients have reduced SOD2 expression. Some THAP1 mutations (C54Y and F81L) decrease THAP1 protein stability, providing an additional pathogenic mechanism of dosage insufficiency.","method":"ChIP-seq, microarray transcriptional profiling, western blot in patient fibroblasts","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq identifies direct target gene, validated in patient cells","pmids":["32112337"],"is_preprint":false},{"year":2011,"finding":"A DYT6 truncation mutation (Asp191Thrfs*9) that disrupts the nuclear localization signal leads to altered subcellular distribution, with protein detected outside the nucleus, suggesting disrupted nuclear import as a pathogenic mechanism.","method":"Subcellular localization by immunofluorescence in transfected cells","journal":"European journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 — single localization experiment without functional follow-up","pmids":["21847143"],"is_preprint":false},{"year":2012,"finding":"THAP1 truncation mutations (F22fs71X and F25fs53X) alter subcellular distribution with protein detected in both cytoplasm and nucleus, whereas missense mutations (C54F and L180S) result in predominantly nuclear localization similar to wild-type.","method":"Immunofluorescence microscopy and western blot in transfected HEK-293T cells","journal":"Parkinsonism & related disorders","confidence":"Low","confidence_rationale":"Tier 3 — localization experiment in overexpression system without functional validation","pmids":["22652465"],"is_preprint":false},{"year":2014,"finding":"In mouse neurons, THAP1 exists as multiple protein species including a unique neuronal 50-kDa species that is exclusively nuclear and distinct from the predicted 25-kDa form. This 50-kDa species is found only in brain and testes and is proposed to result from post-translational modification.","method":"Western blotting with multiple antibodies, immunoprecipitation, DNA oligonucleotide affinity chromatography, subcellular fractionation","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 — multiple antibodies and IP confirmation of a unique neural protein species with nuclear localization","pmids":["25231164"],"is_preprint":false},{"year":2026,"finding":"THAP1 functions as a maternal effect factor in mouse oocytes, activating a critical subset of genes including Rrm1 (ribonucleotide reductase). Oocyte-specific deletion of Thap1 causes 1-2-cell arrest and impaired zygotic genome activation. Overexpression of Rrm1 in zygotes almost fully rescues the 2-cell progression and ZGA defects, establishing THAP1→Rrm1→dNTP production as the mechanistic pathway.","method":"Oocyte-specific conditional knockout, zygotic genome activation assays, low-input metabolome profiling, Rrm1 overexpression rescue","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1–2 — conditional KO with defined molecular mechanism and in vivo rescue experiment","pmids":["41731150"],"is_preprint":false}],"current_model":"THAP1 is a nuclear zinc-finger transcription factor that uses its C2CH THAP domain to bind specific 11-nucleotide DNA sequences and recruit co-factors including HCF-1 and OGT to regulate target genes (RRM1, TOR1A, PSMB5, GusB, SHLD1, SOD2) involved in cell-cycle progression, proteasome homeostasis, DNA double-strand break repair choice, and oligodendrocyte maturation/myelination; it autoregulates its own expression, homodimerizes via a C-terminal coiled-coil leucine-zipper region, interacts with Par-4 at PML nuclear bodies to promote apoptosis, and in neurons controls myelination timing by regulating glycosaminoglycan catabolism through GusB and by facilitating YY1 DNA occupancy at OL maturation gene promoters, with DYT6 dystonia-causing mutations disrupting these activities through impaired DNA binding, reduced protein stability, altered nuclear localization, or failure to organize an active transcription complex."},"narrative":{"teleology":[{"year":2003,"claim":"Before THAP1's DNA-binding or transcriptional functions were known, its localization to PML nuclear bodies and interaction with Par-4 established it as a nuclear factor with proapoptotic activity, raising the question of how its THAP domain contributes to function.","evidence":"Co-IP, immunofluorescence, and apoptosis assays in mammalian cells","pmids":["12717420"],"confidence":"High","gaps":["Mechanism by which THAP1 potentiates apoptosis beyond Par-4 interaction was not defined","Whether THAP domain contributed via DNA binding was unknown"]},{"year":2005,"claim":"The THAP domain was established as a zinc-dependent, sequence-specific DNA-binding module recognizing an 11-nucleotide consensus, resolving whether THAP1 is a bona fide transcription factor.","evidence":"SELEX, site-directed mutagenesis of C2CH residues, zinc chelation assay in vitro","pmids":["15863623"],"confidence":"High","gaps":["No endogenous genomic targets identified yet","No in vivo binding demonstrated"]},{"year":2006,"claim":"Identification of RRM1 as a direct in vivo transcriptional target via ChIP demonstrated that THAP1 functions as a cell-cycle regulator controlling pRB/E2F target genes and G1/S progression in endothelial cells.","evidence":"ChIP, microarray profiling, RNAi, and retroviral overexpression in endothelial cells","pmids":["17003378"],"confidence":"High","gaps":["Cofactors mediating transcriptional regulation were unknown","Whether cell-cycle role extends beyond endothelial cells was untested"]},{"year":2007,"claim":"NMR structure of the THAP zinc finger revealed its unique fold—an antiparallel β-sheet with a loop-helix-loop insertion—and mapped the DNA-contact surface, providing the structural basis for understanding pathogenic mutations.","evidence":"Multidimensional NMR, alanine scanning mutagenesis","pmids":["18073205"],"confidence":"High","gaps":["No structure of THAP domain bound to DNA","Full-length THAP1 structure not determined"]},{"year":2009,"claim":"Genetic linkage of THAP1 mutations to DYT6 primary torsion dystonia, combined with demonstration that the causative missense mutation impairs DNA binding, established THAP1 as a dystonia gene and transcriptional dysregulation as a disease mechanism.","evidence":"Family-based genetic mapping followed by DNA-binding assay of mutant protein","pmids":["19182804"],"confidence":"Medium","gaps":["Only one mutation tested functionally","Neural cell-type-specific consequences were unexplored","Whether all DYT6 mutations impair DNA binding was unknown"]},{"year":2010,"claim":"Two advances resolved THAP1's cofactor recruitment and a disease-relevant target: (1) THAP1 recruits HCF-1 and OGT via a conserved HBM motif to activate RRM1, and (2) THAP1 directly binds and represses the TOR1A promoter, linking two dystonia genes in a common pathway.","evidence":"Mass spectrometry, Co-IP, ChIP, RNAi (for HCF-1/OGT); EMSA, ChIP-qPCR, luciferase assays (for TOR1A), replicated across two labs","pmids":["20200153","20976771","20865765"],"confidence":"High","gaps":["Whether HCF-1 is required at all THAP1 target promoters was unknown","Functional consequence of TOR1A derepression in neurons not tested"]},{"year":2011,"claim":"Mapping of the homodimerization domain to a C-terminal coiled-coil (residues 154–166) established that THAP1 functions as a dimer, while showing that most DYT6 coiled-coil mutations do not disrupt dimerization, pointing to other pathogenic mechanisms.","evidence":"Co-IP with domain deletions and systematic mutant analysis","pmids":["21752024"],"confidence":"Medium","gaps":["Functional significance of dimerization for transcriptional activity was not tested","Single-lab Co-IP without reciprocal pull-down for some mutants"]},{"year":2012,"claim":"Biophysical analysis of DYT6 THAP-domain mutations revealed that reduced protein thermostability—not uniformly abolished DNA binding—is a major pathogenic mechanism, with some mutants unfolding below 37°C.","evidence":"NMR, DSF, ITC, fluorescence spectroscopy on multiple disease mutants","pmids":["22844099"],"confidence":"High","gaps":["Whether reduced stability translates to reduced protein levels in patient neurons was not shown","No in vivo validation of thermostability model"]},{"year":2014,"claim":"Discovery of THAP1 autoregulation—binding its own promoter to repress transcription—explained how DYT6 mutations cause elevated THAP1 levels, establishing a negative feedback loop disrupted in disease.","evidence":"ChIP, luciferase reporters, RT-qPCR, proteasome inhibitor experiments","pmids":["25088175"],"confidence":"Medium","gaps":["Autoregulatory dynamics not measured in neuronal cells","Whether proteasomal degradation of excess THAP1 is a primary clearance mechanism in vivo was not confirmed"]},{"year":2017,"claim":"Conditional knockout in mouse CNS revealed that THAP1 is essential for oligodendrocyte maturation and myelination timing, acting cell-autonomously to facilitate YY1 DNA occupancy at OL maturation gene promoters—providing the first neural cell-type-specific mechanism for DYT6 dystonia.","evidence":"Conditional KO mouse, purified OL progenitor assays, ChIP for YY1","pmids":["28697333"],"confidence":"High","gaps":["How THAP1 promotes YY1 binding mechanistically was not resolved","Whether myelination defects are the primary cause of dystonia motor phenotype was unclear"]},{"year":2021,"claim":"Two new direct THAP1 target pathways were uncovered: (1) GusB regulation controls GAG catabolism in OPCs, with GAG accumulation autoinhibiting maturation (rescuable by β-glucuronidase), and (2) SHLD1 regulation with YY1/HCF1 controls DNA DSB repair pathway choice, conferring PARP inhibitor resistance upon THAP1 loss.","evidence":"ChIP, conditional KO rescue with exogenous enzymes/viral overexpression (GusB); ChIP, genetic epistasis, PARP inhibitor sensitivity assays (SHLD1)","pmids":["34312226","33857404"],"confidence":"High","gaps":["Whether SHLD1 dysregulation contributes to dystonia pathology is unknown","GAG catabolism pathway not validated in human OPCs"]},{"year":2022,"claim":"The DYT6 F81L knockin mouse showed that this mutation does not abolish THAP1 DNA binding but instead prevents YY1 recruitment, establishing that failure to organize an active transcription complex—not loss of DNA binding per se—is a distinct pathogenic mechanism.","evidence":"Knockin mouse, ChIP for THAP1 and YY1, myelination assays","pmids":["34686877"],"confidence":"High","gaps":["Structural basis for how F81L disrupts YY1 recruitment is unknown","Whether this mechanism applies to other THAP domain mutations is untested"]},{"year":2022,"claim":"Epigenomic profiling across patient cortex, iPSC-neurons, and KO models revealed that THAP1 directly targets only a minority of dysregulated genes; broader transcriptional effects are mediated indirectly through SP1 and SP4, expanding the model from direct target regulation to a hierarchical transcription factor network.","evidence":"ChIP-seq and RNA-seq across patient tissue, iPSC-derived neurons, rat KO, and cell lines","pmids":["35015830"],"confidence":"Medium","gaps":["SP1/SP4 regulation by THAP1 not shown to be direct at all loci","Cell-type specificity of indirect effects not fully delineated"]},{"year":2025,"claim":"THAP1 was identified as a direct transcriptional regulator of PSMB5, and its loss causes defective proteasome assembly and impaired proteostasis—establishing proteasome homeostasis as a fundamental THAP1-dependent process, validated by deep mutational scanning of the entire protein.","evidence":"Genome-wide genetic screen, ChIP, proteasome activity assays, deep mutational scanning, PSMB5 rescue, replicated across two independent studies","pmids":["39952963","39929834"],"confidence":"High","gaps":["Whether proteostasis defects contribute to DYT6 neuronal dysfunction is unknown","Relative importance of PSMB5 versus other targets in disease not established"]},{"year":2025,"claim":"THAP1 was discovered to function as a maternal-effect factor activating Rrm1 in oocytes; its loss causes zygotic genome activation failure and 1–2-cell arrest, rescuable by Rrm1 overexpression, revealing an unexpected role in the earliest stages of embryonic development.","evidence":"Oocyte-specific conditional KO, ZGA assays, low-input metabolomics, Rrm1 rescue","pmids":["41731150"],"confidence":"High","gaps":["Whether THAP1 maternal function is relevant to human fertility is unknown","Full set of THAP1 maternal targets beyond Rrm1 not characterized"]},{"year":null,"claim":"Key unresolved questions include the structural basis of THAP1-mediated YY1 and HCF-1 co-recruitment, the relative contribution of myelination versus neuronal transcriptional defects to DYT6 dystonia, and whether proteasome homeostasis dysfunction is a primary driver of disease pathology.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal or cryo-EM structure of THAP1 with any partner or DNA","Causal hierarchy among THAP1 target pathways in dystonia neurons not established","Full-length THAP1 structure including coiled-coil domain not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,3,5,8,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,6,9,11,13,14,17,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,20,21,22]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,5,6,9,14,16,17,23]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,6]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[14]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[17,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,10]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,13]}],"complexes":["THAP1 homodimer","THAP1–HCF-1–OGT complex","THAP1–Par-4 complex"],"partners":["HCF1","OGT","PAWR","YY1","SP1","SP4"],"other_free_text":[]},"mechanistic_narrative":"THAP1 is a nuclear zinc-finger transcription factor that uses its N-terminal C2CH THAP domain to recognize specific DNA sequences in target gene promoters and recruits cofactors HCF-1 and OGT to regulate cell-cycle progression, proteasome homeostasis, DNA double-strand break repair pathway choice, myelination, and zygotic genome activation [PMID:15863623, PMID:20200153, PMID:17003378, PMID:39952963, PMID:33857404, PMID:28697333, PMID:41731150]. THAP1 directly activates or represses key target genes—including RRM1, TOR1A, PSMB5, SHLD1, GusB, and SOD2—and autoregulates its own promoter; it homodimerizes through a C-terminal coiled-coil domain and cooperates with transcription factors YY1 and SP1/SP4 to control broader transcriptional programs, particularly in oligodendrocytes where it governs myelination timing through glycosaminoglycan catabolism and YY1 DNA occupancy [PMID:25088175, PMID:34312226, PMID:34686877, PMID:35015830]. Loss of THAP1-mediated PSMB5 transcription impairs proteasome assembly and proteostasis [PMID:39929834]. Mutations in THAP1 cause DYT6 primary torsion dystonia through diverse mechanisms including impaired DNA binding, reduced protein thermostability, disrupted nuclear localization, and failure to assemble active transcription complexes with partner factors [PMID:19182804, PMID:22844099, PMID:34686877]."},"prefetch_data":{"uniprot":{"accession":"Q9NVV9","full_name":"THAP domain-containing protein 1","aliases":[],"length_aa":213,"mass_kda":24.9,"function":"DNA-binding transcription regulator that regulates endothelial cell proliferation and G1/S cell-cycle progression. Specifically binds the 5'-[AT]NTNN[GT]GGCA[AGT]-3' core DNA sequence and acts by modulating expression of pRB-E2F cell-cycle target genes, including RRM1. Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1. May also have pro-apoptotic activity by potentiating both serum-withdrawal and TNF-induced apoptosis","subcellular_location":"Nucleus, nucleoplasm; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/Q9NVV9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/THAP1","classification":"Common Essential","n_dependent_lines":1068,"n_total_lines":1208,"dependency_fraction":0.8841059602649006},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/THAP1","total_profiled":1310},"omim":[{"mim_id":"617284","title":"DYSTONIA 28, CHILDHOOD-ONSET; DYT28","url":"https://www.omim.org/entry/617284"},{"mim_id":"612532","title":"THAP DOMAIN-CONTAINING PROTEIN 3; THAP3","url":"https://www.omim.org/entry/612532"},{"mim_id":"612531","title":"THAP DOMAIN-CONTAINING PROTEIN 2; THAP2","url":"https://www.omim.org/entry/612531"},{"mim_id":"609520","title":"THAP DOMAIN-CONTAINING PROTEIN 1; THAP1","url":"https://www.omim.org/entry/609520"},{"mim_id":"606834","title":"LYSINE-SPECIFIC METHYLTRANSFERASE 2B; KMT2B","url":"https://www.omim.org/entry/606834"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/THAP1"},"hgnc":{"alias_symbol":["FLJ10477","4833431A01Rik"],"prev_symbol":["DYT6"]},"alphafold":{"accession":"Q9NVV9","domains":[{"cath_id":"-","chopping":"1-82","consensus_level":"medium","plddt":78.2461,"start":1,"end":82},{"cath_id":"1.20.5","chopping":"139-200","consensus_level":"high","plddt":86.0952,"start":139,"end":200}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVV9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVV9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVV9-F1-predicted_aligned_error_v6.png","plddt_mean":70.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=THAP1","jax_strain_url":"https://www.jax.org/strain/search?query=THAP1"},"sequence":{"accession":"Q9NVV9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NVV9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NVV9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVV9"}},"corpus_meta":[{"pmid":"19182804","id":"PMC_19182804","title":"Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19182804","citation_count":244,"is_preprint":false},{"pmid":"19345147","id":"PMC_19345147","title":"Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19345147","citation_count":130,"is_preprint":false},{"pmid":"15863623","id":"PMC_15863623","title":"The THAP domain of THAP1 is a large C2CH module with zinc-dependent sequence-specific DNA-binding activity.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15863623","citation_count":124,"is_preprint":false},{"pmid":"12717420","id":"PMC_12717420","title":"THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12717420","citation_count":123,"is_preprint":false},{"pmid":"19345148","id":"PMC_19345148","title":"Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19345148","citation_count":116,"is_preprint":false},{"pmid":"17003378","id":"PMC_17003378","title":"The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17003378","citation_count":116,"is_preprint":false},{"pmid":"20200153","id":"PMC_20200153","title":"The THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20200153","citation_count":91,"is_preprint":false},{"pmid":"20083799","id":"PMC_20083799","title":"Novel THAP1 sequence variants in primary dystonia.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20083799","citation_count":83,"is_preprint":false},{"pmid":"20211909","id":"PMC_20211909","title":"THAP1 mutations (DYT6) are an additional cause of early-onset dystonia.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20211909","citation_count":82,"is_preprint":false},{"pmid":"20976771","id":"PMC_20976771","title":"The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6).","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20976771","citation_count":75,"is_preprint":false},{"pmid":"20687191","id":"PMC_20687191","title":"DYT6 dystonia: mutation screening, phenotype, and response to deep brain stimulation.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20687191","citation_count":75,"is_preprint":false},{"pmid":"22377579","id":"PMC_22377579","title":"Genotype-phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22377579","citation_count":72,"is_preprint":false},{"pmid":"18073205","id":"PMC_18073205","title":"Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18073205","citation_count":68,"is_preprint":false},{"pmid":"20865765","id":"PMC_20865765","title":"Direct interaction between causative genes of DYT1 and DYT6 primary dystonia.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20865765","citation_count":66,"is_preprint":false},{"pmid":"21949105","id":"PMC_21949105","title":"Pallidal deep brain stimulation for DYT6 dystonia.","date":"2011","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21949105","citation_count":66,"is_preprint":false},{"pmid":"29364887","id":"PMC_29364887","title":"Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29364887","citation_count":63,"is_preprint":false},{"pmid":"24135862","id":"PMC_24135862","title":"SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia.","date":"2013","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/24135862","citation_count":58,"is_preprint":false},{"pmid":"17702011","id":"PMC_17702011","title":"Narrowing the DYT6 dystonia region and evidence for locus heterogeneity in the Amish-Mennonites.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17702011","citation_count":54,"is_preprint":false},{"pmid":"22903657","id":"PMC_22903657","title":"THAP1 mutations and dystonia phenotypes: genotype phenotype correlations.","date":"2012","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/22903657","citation_count":52,"is_preprint":false},{"pmid":"21793105","id":"PMC_21793105","title":"DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21793105","citation_count":50,"is_preprint":false},{"pmid":"28697333","id":"PMC_28697333","title":"The DYT6 Dystonia Protein THAP1 Regulates Myelination within the Oligodendrocyte Lineage.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/28697333","citation_count":49,"is_preprint":false},{"pmid":"26376866","id":"PMC_26376866","title":"Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26376866","citation_count":47,"is_preprint":false},{"pmid":"21847143","id":"PMC_21847143","title":"Identification and functional analysis of novel THAP1 mutations.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21847143","citation_count":42,"is_preprint":false},{"pmid":"19908325","id":"PMC_19908325","title":"Mutation screening of the DYT6/THAP1 gene in Italy.","date":"2009","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/19908325","citation_count":37,"is_preprint":false},{"pmid":"20687193","id":"PMC_20687193","title":"Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20687193","citation_count":35,"is_preprint":false},{"pmid":"21425335","id":"PMC_21425335","title":"Homozygous THAP1 mutations as cause of early-onset generalized dystonia.","date":"2011","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/21425335","citation_count":33,"is_preprint":false},{"pmid":"23975424","id":"PMC_23975424","title":"Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23975424","citation_count":31,"is_preprint":false},{"pmid":"28579396","id":"PMC_28579396","title":"THAP1: Role in Mouse Embryonic Stem Cell Survival and Differentiation.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28579396","citation_count":30,"is_preprint":false},{"pmid":"24500857","id":"PMC_24500857","title":"Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24500857","citation_count":30,"is_preprint":false},{"pmid":"20825472","id":"PMC_20825472","title":"Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20825472","citation_count":30,"is_preprint":false},{"pmid":"26486352","id":"PMC_26486352","title":"Long-term effect on dystonia after pallidal deep brain stimulation (DBS) in three members of a family with a THAP1 mutation.","date":"2015","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26486352","citation_count":30,"is_preprint":false},{"pmid":"30590536","id":"PMC_30590536","title":"Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30590536","citation_count":29,"is_preprint":false},{"pmid":"20669277","id":"PMC_20669277","title":"Prevalence of THAP1 sequence variants in German patients with primary dystonia.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20669277","citation_count":29,"is_preprint":false},{"pmid":"25359437","id":"PMC_25359437","title":"Deep brain stimulation of the thalamic ventral lateral anterior nucleus for DYT6 dystonia.","date":"2014","source":"Stereotactic and functional neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/25359437","citation_count":29,"is_preprint":false},{"pmid":"21752024","id":"PMC_21752024","title":"Dimerization of the DYT6 dystonia protein, THAP1, requires residues within the coiled-coil domain.","date":"2011","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21752024","citation_count":26,"is_preprint":false},{"pmid":"33857404","id":"PMC_33857404","title":"The dystonia gene THAP1 controls DNA double-strand break repair choice.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33857404","citation_count":24,"is_preprint":false},{"pmid":"22844099","id":"PMC_22844099","title":"Towards the classification of DYT6 dystonia mutants in the DNA-binding domain of THAP1.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22844099","citation_count":21,"is_preprint":false},{"pmid":"23219941","id":"PMC_23219941","title":"Neural expression of the transcription factor THAP1 during development in rat.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23219941","citation_count":21,"is_preprint":false},{"pmid":"34672987","id":"PMC_34672987","title":"Dystonia-specific mutations in THAP1 alter transcription of genes associated with neurodevelopment and myelin.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34672987","citation_count":20,"is_preprint":false},{"pmid":"25088175","id":"PMC_25088175","title":"THAP1, the gene mutated in DYT6 dystonia, autoregulates its own expression.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25088175","citation_count":20,"is_preprint":false},{"pmid":"24862462","id":"PMC_24862462","title":"Combined occurrence of a novel TOR1A and a THAP1 mutation in primary dystonia.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24862462","citation_count":18,"is_preprint":false},{"pmid":"31158945","id":"PMC_31158945","title":"The Effect of Globus Pallidus Interna Deep Brain Stimulation on a Dystonia Patient with the GNAL Mutation Compared to Patients with DYT1 and DYT6.","date":"2019","source":"Journal of movement disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31158945","citation_count":18,"is_preprint":false},{"pmid":"21370264","id":"PMC_21370264","title":"The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia.","date":"2011","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/21370264","citation_count":18,"is_preprint":false},{"pmid":"20925076","id":"PMC_20925076","title":"Screening of Brazilian families with primary dystonia reveals a novel THAP1 mutation and a de novo TOR1A GAG deletion.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20925076","citation_count":18,"is_preprint":false},{"pmid":"26610312","id":"PMC_26610312","title":"DYT6 Dystonia: A Neuropathological Study.","date":"2015","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26610312","citation_count":18,"is_preprint":false},{"pmid":"24936516","id":"PMC_24936516","title":"A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia.","date":"2014","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24936516","citation_count":17,"is_preprint":false},{"pmid":"21800139","id":"PMC_21800139","title":"THAP1/DYT6 sequence variants in non-DYT1 early-onset primary dystonia in China and their effects on RNA expression.","date":"2011","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21800139","citation_count":17,"is_preprint":false},{"pmid":"22652465","id":"PMC_22652465","title":"Subcellular distribution of THAP1 and alterations in the microstructure of brain white matter in DYT6 dystonia.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22652465","citation_count":16,"is_preprint":false},{"pmid":"32112337","id":"PMC_32112337","title":"Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia.","date":"2020","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/32112337","citation_count":15,"is_preprint":false},{"pmid":"33547842","id":"PMC_33547842","title":"Linking Penetrance and Transcription in DYT-THAP1: Insights From a Human iPSC-Derived Cortical Model.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/33547842","citation_count":15,"is_preprint":false},{"pmid":"34312226","id":"PMC_34312226","title":"THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34312226","citation_count":15,"is_preprint":false},{"pmid":"23180184","id":"PMC_23180184","title":"Mutation screening of the DYT6/THAP1 gene in Serbian patients with primary dystonia.","date":"2012","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23180184","citation_count":13,"is_preprint":false},{"pmid":"34686877","id":"PMC_34686877","title":"A pathogenic DYT-THAP1 dystonia mutation causes hypomyelination and loss of YY1 binding.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34686877","citation_count":12,"is_preprint":false},{"pmid":"27913194","id":"PMC_27913194","title":"Genetic screening of THAP1 in primary dystonia patients of India.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27913194","citation_count":12,"is_preprint":false},{"pmid":"34095114","id":"PMC_34095114","title":"Reduced Expression of GABA  Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34095114","citation_count":11,"is_preprint":false},{"pmid":"31133547","id":"PMC_31133547","title":"Intracranial calcifications and dystonia associated with a novel deletion of chromosome 8p11.2 encompassing SLC20A2 and THAP1.","date":"2019","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/31133547","citation_count":11,"is_preprint":false},{"pmid":"35015830","id":"PMC_35015830","title":"DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35015830","citation_count":10,"is_preprint":false},{"pmid":"25231164","id":"PMC_25231164","title":"Dystonia type 6 gene product Thap1: identification of a 50 kDa DNA-binding species in neuronal nuclear fractions.","date":"2014","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/25231164","citation_count":10,"is_preprint":false},{"pmid":"21839475","id":"PMC_21839475","title":"Novel THAP1 gene mutations in patients with primary dystonia from southwest China.","date":"2011","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21839475","citation_count":10,"is_preprint":false},{"pmid":"28299530","id":"PMC_28299530","title":"In-depth Characterization of the Homodimerization Domain of the Transcription Factor THAP1 and Dystonia-Causing Mutations Therein.","date":"2017","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/28299530","citation_count":10,"is_preprint":false},{"pmid":"24976531","id":"PMC_24976531","title":"Novel THAP1 variants in Brazilian patients with idiopathic isolated dystonia.","date":"2014","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24976531","citation_count":10,"is_preprint":false},{"pmid":"25385508","id":"PMC_25385508","title":"High variability of clinical symptoms in a Polish family with a novel THAP1 mutation.","date":"2014","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25385508","citation_count":8,"is_preprint":false},{"pmid":"39952963","id":"PMC_39952963","title":"The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39952963","citation_count":7,"is_preprint":false},{"pmid":"24757586","id":"PMC_24757586","title":"DYT6 in Brazil: Genetic Assessment and Clinical Characteristics of Patients.","date":"2014","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24757586","citation_count":7,"is_preprint":false},{"pmid":"39929834","id":"PMC_39929834","title":"Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39929834","citation_count":6,"is_preprint":false},{"pmid":"23439738","id":"PMC_23439738","title":"Spatial Discrimination Threshold Abnormalities are not Detected in a Pilot Study of DYT6 Dystonia Mutation Carriers.","date":"2012","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23439738","citation_count":6,"is_preprint":false},{"pmid":"30316041","id":"PMC_30316041","title":"Generation and characterization of eight human-derived iPSC lines from affected and unaffected THAP1 mutation carriers.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30316041","citation_count":4,"is_preprint":false},{"pmid":"33175450","id":"PMC_33175450","title":"Mutational spectrum of GNAL, THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review.","date":"2020","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33175450","citation_count":3,"is_preprint":false},{"pmid":"31367947","id":"PMC_31367947","title":"Cerebellar Involvement in DYT-THAP1 Dystonia.","date":"2019","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31367947","citation_count":3,"is_preprint":false},{"pmid":"36096774","id":"PMC_36096774","title":"A case of novel DYT6 dystonia variant with serious complications after deep brain stimulation therapy: a case report.","date":"2022","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36096774","citation_count":3,"is_preprint":false},{"pmid":"26940431","id":"PMC_26940431","title":"New THAP1 mutation and role of putative modifier in TOR1A.","date":"2016","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/26940431","citation_count":2,"is_preprint":false},{"pmid":"34802187","id":"PMC_34802187","title":"Pharmacological perturbation reveals deficits in D2 receptor responses in Thap1 null mice.","date":"2021","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34802187","citation_count":2,"is_preprint":false},{"pmid":"39180203","id":"PMC_39180203","title":"MS4A3 Promotes the Chemosensitivity of Lung Cancer via THAP1/EGFR Pathways.","date":"2024","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/39180203","citation_count":2,"is_preprint":false},{"pmid":"26803725","id":"PMC_26803725","title":"Lack of association between TOR1A and THAP1 mutations and sporadic adult-onset primary focal dystonia in a Chinese population.","date":"2016","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/26803725","citation_count":2,"is_preprint":false},{"pmid":"26087139","id":"PMC_26087139","title":"Screening for THAP1 Mutations in Polish Patients with Dystonia Shows Known and Novel Substitutions.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26087139","citation_count":2,"is_preprint":false},{"pmid":"38835919","id":"PMC_38835919","title":"Emerging role of a systems biology approach to elucidate factors of reduced penetrance: transcriptional changes in THAP1-linked dystonia as an example.","date":"2022","source":"Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/38835919","citation_count":2,"is_preprint":false},{"pmid":"39732371","id":"PMC_39732371","title":"Peripheral nerve injury induces dystonia-like movements and dysregulation in the energy metabolism: A multi-omics descriptive study in Thap1+/- mice.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39732371","citation_count":2,"is_preprint":false},{"pmid":"38737544","id":"PMC_38737544","title":"Transcriptional regulatory network for neuron-glia interactions and its implication for DYT6 dystonia.","date":"2023","source":"Dystonia (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38737544","citation_count":1,"is_preprint":false},{"pmid":"40735195","id":"PMC_40735195","title":"Case report: Lingual dystonia symptoms treated with botulinum toxin in patients with THAP1 mutation.","date":"2024","source":"Dystonia (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40735195","citation_count":1,"is_preprint":false},{"pmid":"34998426","id":"PMC_34998426","title":"Changes in pallidal neural activity following long-term symptom improvement from botulinum toxin treatment in DYT6 dystonia: a case report.","date":"2022","source":"Journal of medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/34998426","citation_count":1,"is_preprint":false},{"pmid":"25168324","id":"PMC_25168324","title":"Intrafamilial variability of the primary dystonia DYT6 phenotype caused by p.Cys5Trp mutation in THAP1 gene.","date":"2014","source":"Neurologia i neurochirurgia polska","url":"https://pubmed.ncbi.nlm.nih.gov/25168324","citation_count":1,"is_preprint":false},{"pmid":"41731150","id":"PMC_41731150","title":"THAP1 is a maternal effect factor required for the first cell cycle via Rrm1 in early mouse embryos.","date":"2026","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/41731150","citation_count":0,"is_preprint":false},{"pmid":"37637848","id":"PMC_37637848","title":"Generalized Dystonia Due to a Pathogenic THAP1 Variant Showing Sustained Response to Globus Pallidus Deep Brain Stimulation.","date":"2023","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37637848","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.02.24316741","title":"Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.24316741","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40312,"output_tokens":5793,"usd":0.103915},"stage2":{"model":"claude-opus-4-6","input_tokens":9399,"output_tokens":3844,"usd":0.214643},"total_usd":0.318558,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"The THAP domain of THAP1 is a zinc-dependent sequence-specific DNA-binding domain belonging to the zinc-finger superfamily. In vitro binding-site selection identified an 11-nucleotide consensus DNA-binding sequence recognized by the THAP domain. Site-directed mutagenesis of the C2CH motif cysteines and histidine abolished DNA binding, and zinc chelation with 1,10-o-phenanthroline confirmed zinc dependency. Four conserved residues (P, W, F, P) were also required for DNA binding.\",\n      \"method\": \"In vitro binding-site selection (SELEX), site-directed mutagenesis, zinc chelation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding with mutagenesis of multiple residues confirming mechanism\",\n      \"pmids\": [\"15863623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"THAP1 localizes to PML nuclear bodies and interacts with the proapoptotic protein Par-4. THAP1 potentiates serum withdrawal- and TNF-alpha-induced apoptosis. The THAP domain is not required for Par-4 binding or PML NB localization but is essential for THAP1 proapoptotic activity.\",\n      \"method\": \"Subcellular localization by immunofluorescence, Co-immunoprecipitation, functional apoptosis assays, domain deletion analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal localization studies with domain mutagenesis and functional readout\",\n      \"pmids\": [\"12717420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"THAP1 regulates endothelial cell proliferation and G1/S cell-cycle progression by coordinated repression of pRB/E2F cell-cycle target genes. Chromatin immunoprecipitation showed endogenous THAP1 binds a consensus THAP1-binding site in the RRM1 promoter in vivo, establishing RRM1 as a direct transcriptional target. Both overexpression and RNAi silencing of THAP1 inhibit EC proliferation, indicating an optimal expression range is required.\",\n      \"method\": \"Retroviral gene transfer, RNA interference, microarray expression profiling, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, RNAi, OE) with defined cellular phenotype\",\n      \"pmids\": [\"17003378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NMR structure of the THAP zinc finger of THAP1 revealed an atypical ~80-residue zinc finger with a short antiparallel beta-sheet and a long loop-helix-loop insertion between C2CH zinc-coordinating residues. Alanine scanning mutagenesis and NMR chemical shift perturbation mapped the DNA-binding interface to a highly positively charged surface with multiple lysine and arginine residues.\",\n      \"method\": \"Multidimensional NMR spectroscopy, deletion mutagenesis, alanine scanning mutagenesis, NMR chemical shift perturbation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — 3D structure determined by NMR with mutagenesis validation of DNA-binding residues\",\n      \"pmids\": [\"18073205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A missense mutation in THAP1 found in DYT6 primary torsion dystonia families impairs DNA binding of the THAP domain, suggesting transcriptional dysregulation contributes to the disease phenotype.\",\n      \"method\": \"Genetic identification followed by DNA binding assay demonstrating functional impairment of mutant THAP1\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional DNA-binding assay on disease mutation, single study\",\n      \"pmids\": [\"19182804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"THAP1 binds directly to the core promoter of TOR1A (DYT1) and represses its expression. Dystonia-6-associated mutant THAP1 shows decreased repression of TOR1A compared to wild-type. This was demonstrated by electrophoretic mobility shift assay (EMSA) and ChIP-qPCR.\",\n      \"method\": \"Electromobility shift assay (EMSA), chromatin immunoprecipitation quantitative PCR (ChIP-qPCR), luciferase reporter assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding demonstrated by EMSA and ChIP, replicated by two independent labs (PMID 20976771 and 20865765)\",\n      \"pmids\": [\"20976771\", \"20865765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"THAP1 associates with the transcriptional coactivator HCF-1 and O-GlcNAc transferase (OGT) in vivo through a conserved HCF-1-binding motif (HBM). THAP1 mediates recruitment of HCF-1 to the RRM1 promoter during endothelial cell proliferation, and HCF-1 is essential for transcriptional activation of RRM1.\",\n      \"method\": \"Proteomic analysis (mass spectrometry), in vitro binding, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction confirmed by Co-IP and ChIP with functional RNAi validation\",\n      \"pmids\": [\"20200153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"THAP1 self-associates (dimerizes) through a region within its C-terminal coiled-coil domain, specifically residues 154–166 containing leucine-zipper-like elements. The DYT6 frameshift mutation Q154fs180X, which removes most of the coiled-coil domain, abolishes self-association, whereas other disease mutations within the coiled-coil (C54Y, F81L, ΔF132, T142A, I149T, A166T) do not disrupt dimerization.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion and truncation analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab Co-IP with systematic mutant analysis\",\n      \"pmids\": [\"21752024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NMR, fluorescence, DSF, and ITC analyses of DYT6 missense mutations within the THAP DNA-binding domain showed that mutations do not uniformly abolish DNA binding; some mutants bind DNA stronger than wild-type. However, some mutations alter DNA-binding specificity and most dramatically reduce protein thermostability (unfolding temperatures below 37°C for some mutants vs. 46°C for wild-type), suggesting reduced folded protein population under physiological conditions contributes to disease.\",\n      \"method\": \"NMR spectroscopy, fluorescence spectroscopy, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC)\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods in one study examining mechanism of pathogenic mutations\",\n      \"pmids\": [\"22844099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"THAP1 autoregulates its own expression by binding to its own promoter and repressing transcription. Using luciferase reporter assays and quantitative ChIP, the THAP1 minimal promoter was mapped to a 480 bp fragment. DYT6-causing mutations disrupt this autoregulation, leading to elevated THAP1 levels. Overexpressed THAP1 is degraded via the proteasome.\",\n      \"method\": \"Luciferase reporter gene assays, quantitative ChIP, RT-qPCR, proteasome inhibitor experiments\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assays in single lab demonstrating feedback loop\",\n      \"pmids\": [\"25088175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Par-4 and THAP1 form a protein complex through interaction of their carboxyl termini. THAP1 binds the CCAR1 promoter through its N-terminal zinc-dependent DNA-binding domain. The Par-4/THAP1 complex activates CCAR1 promoter and induces apoptosis. Additionally, Par-4/THAP1 and Notch3 competitively bind the CCAR1 promoter and competitively regulate alternative pre-mRNA splicing of CCAR1 via splicing factors SRp40 and SRp55.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, ChIP, splicing assay, domain deletion analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple methods but single lab; mechanistic detail on complex and splicing regulation\",\n      \"pmids\": [\"23975424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"THAP1 is essential for timing myelination initiation during CNS maturation through a cell-autonomous role in the oligodendrocyte (OL) lineage. Conditional deletion of THAP1 in the CNS retards OL maturation, delays myelination, and causes persistent motor deficits. Loss of THAP1 disrupts core OL maturation genes and reduces DNA occupancy of YY1, a transcription factor required for OL maturation.\",\n      \"method\": \"Conditional knockout mouse model, OL progenitor cell purification and developmental assays, ChIP for YY1\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with cell-autonomous rescue experiments and ChIP, replicated across multiple assays\",\n      \"pmids\": [\"28697333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The coiled-coil domain of THAP1 spanning residues 139–185 is responsible for homodimerization, confirmed by yeast-two-hybrid, GST pull-down, and cross-linking assays. Nine reported DYT6-causing missense mutations within this region do not impair dimerization.\",\n      \"method\": \"Yeast-two-hybrid, GST pull-down, formaldehyde cross-linking assay\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — three orthogonal methods in single lab confirming dimerization domain\",\n      \"pmids\": [\"28299530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"THAP1 modulates extracellular matrix (ECM) composition in oligodendrocyte progenitor cells (OPCs) by regulating glycosaminoglycan (GAG) catabolism. THAP1 directly binds to and regulates the GusB gene encoding β-glucuronidase, a lysosomal GAG-catabolic enzyme. Loss of THAP1 causes OPCs to accumulate and secrete excess GAGs, inhibiting maturation through an autoinhibitory mechanism. Applying GAG-degrading enzymes or overexpressing β-glucuronidase rescues Thap1-/- OL maturation deficits in vitro and in vivo.\",\n      \"method\": \"ChIP, loss-of-function mouse model, rescue experiments with exogenous enzymes and viral overexpression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct target gene identified by ChIP, causal mechanism validated by rescue in vitro and in vivo\",\n      \"pmids\": [\"34312226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"THAP1, YY1, and HCF1 bind directly to the SHLD1 (Shieldin component) promoter and cooperatively maintain low basal expression of SHLD1, thereby controlling the balance between end protection and resection during DNA double-strand break repair. Loss of THAP1 alters SHLD1 expression and confers resistance to PARP inhibitors and cisplatin in BRCA1-deficient cells.\",\n      \"method\": \"ChIP, promoter binding assays, genetic epistasis in cell lines and mouse models, PARP inhibitor sensitivity assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct promoter binding, epistasis in multiple model systems, functional consequence on DSB repair\",\n      \"pmids\": [\"33857404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The DYT6 missense mutation F81L (THAP1F81L) impairs THAP1 transcriptional activity and disrupts CNS myelination. THAP1F81L exhibits normal DNA binding but causes significantly reduced DNA binding of its transcriptional partner YY1, indicating that the mutation disrupts assembly of an active transcription complex rather than directly abolishing DNA binding.\",\n      \"method\": \"Knockin mouse model, ChIP for YY1 DNA occupancy, myelination assays, in vitro transcriptional activity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockin model with ChIP showing loss of partner binding as mechanism, supported by functional myelination readout\",\n      \"pmids\": [\"34686877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"THAP1 mutations lead to dysregulation of genes mainly through regulation of SP1 family members SP1 and SP4 in a cell-type-dependent manner, as revealed by epigenomic and transcriptomic analyses in patient frontal cortex, iPSC-derived neurons, heterozygous knockout rat, and knockout cell lines. THAP1 directly targets only a minority of differentially expressed genes; broader transcriptional effects are mediated through SP1/SP4.\",\n      \"method\": \"ChIP-seq, RNA-seq in multiple model systems including patient tissue and iPSC-derived neurons\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq identifies indirect mechanism via SP1/SP4 across multiple model systems\",\n      \"pmids\": [\"35015830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"THAP1 directly regulates expression of PSMB5 (encoding proteasome subunit β5). Depletion of THAP1 disrupts proteasome assembly, reduces proteasome activity, and causes accumulation of ubiquitinated proteins. This was identified by genome-wide genetic screen and confirmed by ChIP demonstrating direct THAP1 binding to the PSMB5 promoter.\",\n      \"method\": \"Genome-wide genetic screen, ChIP, proteasome activity assays, ubiquitinated protein accumulation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide screen followed by ChIP confirmation and direct functional measurement, replicated in two independent studies (PMID 39952963 and 39929834)\",\n      \"pmids\": [\"39952963\", \"39929834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Deep mutational scanning of THAP1 systematically assessed the function of thousands of single amino acid variants, revealing that PSMB5 insufficiency from THAP1 loss leads to defective proteasome assembly and impaired proteostasis. RNA-seq defined THAP1 transcriptional targets, with PSMB5 as a critical direct target.\",\n      \"method\": \"Deep mutational scanning, RNA-seq, proteasome assembly assays, PSMB5 rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — deep mutational scan plus RNA-seq and functional rescue in a single rigorous study\",\n      \"pmids\": [\"39929834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ChIP-seq showed THAP1 directly binds the promoter of SOD2 (superoxide dismutase 2). Overexpression of THAP1 increases SOD2 protein, while fibroblasts from THAP1 patients have reduced SOD2 expression. Some THAP1 mutations (C54Y and F81L) decrease THAP1 protein stability, providing an additional pathogenic mechanism of dosage insufficiency.\",\n      \"method\": \"ChIP-seq, microarray transcriptional profiling, western blot in patient fibroblasts\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq identifies direct target gene, validated in patient cells\",\n      \"pmids\": [\"32112337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A DYT6 truncation mutation (Asp191Thrfs*9) that disrupts the nuclear localization signal leads to altered subcellular distribution, with protein detected outside the nucleus, suggesting disrupted nuclear import as a pathogenic mechanism.\",\n      \"method\": \"Subcellular localization by immunofluorescence in transfected cells\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single localization experiment without functional follow-up\",\n      \"pmids\": [\"21847143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"THAP1 truncation mutations (F22fs71X and F25fs53X) alter subcellular distribution with protein detected in both cytoplasm and nucleus, whereas missense mutations (C54F and L180S) result in predominantly nuclear localization similar to wild-type.\",\n      \"method\": \"Immunofluorescence microscopy and western blot in transfected HEK-293T cells\",\n      \"journal\": \"Parkinsonism & related disorders\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — localization experiment in overexpression system without functional validation\",\n      \"pmids\": [\"22652465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In mouse neurons, THAP1 exists as multiple protein species including a unique neuronal 50-kDa species that is exclusively nuclear and distinct from the predicted 25-kDa form. This 50-kDa species is found only in brain and testes and is proposed to result from post-translational modification.\",\n      \"method\": \"Western blotting with multiple antibodies, immunoprecipitation, DNA oligonucleotide affinity chromatography, subcellular fractionation\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple antibodies and IP confirmation of a unique neural protein species with nuclear localization\",\n      \"pmids\": [\"25231164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"THAP1 functions as a maternal effect factor in mouse oocytes, activating a critical subset of genes including Rrm1 (ribonucleotide reductase). Oocyte-specific deletion of Thap1 causes 1-2-cell arrest and impaired zygotic genome activation. Overexpression of Rrm1 in zygotes almost fully rescues the 2-cell progression and ZGA defects, establishing THAP1→Rrm1→dNTP production as the mechanistic pathway.\",\n      \"method\": \"Oocyte-specific conditional knockout, zygotic genome activation assays, low-input metabolome profiling, Rrm1 overexpression rescue\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — conditional KO with defined molecular mechanism and in vivo rescue experiment\",\n      \"pmids\": [\"41731150\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"THAP1 is a nuclear zinc-finger transcription factor that uses its C2CH THAP domain to bind specific 11-nucleotide DNA sequences and recruit co-factors including HCF-1 and OGT to regulate target genes (RRM1, TOR1A, PSMB5, GusB, SHLD1, SOD2) involved in cell-cycle progression, proteasome homeostasis, DNA double-strand break repair choice, and oligodendrocyte maturation/myelination; it autoregulates its own expression, homodimerizes via a C-terminal coiled-coil leucine-zipper region, interacts with Par-4 at PML nuclear bodies to promote apoptosis, and in neurons controls myelination timing by regulating glycosaminoglycan catabolism through GusB and by facilitating YY1 DNA occupancy at OL maturation gene promoters, with DYT6 dystonia-causing mutations disrupting these activities through impaired DNA binding, reduced protein stability, altered nuclear localization, or failure to organize an active transcription complex.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"THAP1 is a nuclear zinc-finger transcription factor that uses its N-terminal C2CH THAP domain to recognize specific DNA sequences in target gene promoters and recruits cofactors HCF-1 and OGT to regulate cell-cycle progression, proteasome homeostasis, DNA double-strand break repair pathway choice, myelination, and zygotic genome activation [PMID:15863623, PMID:20200153, PMID:17003378, PMID:39952963, PMID:33857404, PMID:28697333, PMID:41731150]. THAP1 directly activates or represses key target genes—including RRM1, TOR1A, PSMB5, SHLD1, GusB, and SOD2—and autoregulates its own promoter; it homodimerizes through a C-terminal coiled-coil domain and cooperates with transcription factors YY1 and SP1/SP4 to control broader transcriptional programs, particularly in oligodendrocytes where it governs myelination timing through glycosaminoglycan catabolism and YY1 DNA occupancy [PMID:25088175, PMID:34312226, PMID:34686877, PMID:35015830]. Loss of THAP1-mediated PSMB5 transcription impairs proteasome assembly and proteostasis [PMID:39929834]. Mutations in THAP1 cause DYT6 primary torsion dystonia through diverse mechanisms including impaired DNA binding, reduced protein thermostability, disrupted nuclear localization, and failure to assemble active transcription complexes with partner factors [PMID:19182804, PMID:22844099, PMID:34686877].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Before THAP1's DNA-binding or transcriptional functions were known, its localization to PML nuclear bodies and interaction with Par-4 established it as a nuclear factor with proapoptotic activity, raising the question of how its THAP domain contributes to function.\",\n      \"evidence\": \"Co-IP, immunofluorescence, and apoptosis assays in mammalian cells\",\n      \"pmids\": [\"12717420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which THAP1 potentiates apoptosis beyond Par-4 interaction was not defined\", \"Whether THAP domain contributed via DNA binding was unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The THAP domain was established as a zinc-dependent, sequence-specific DNA-binding module recognizing an 11-nucleotide consensus, resolving whether THAP1 is a bona fide transcription factor.\",\n      \"evidence\": \"SELEX, site-directed mutagenesis of C2CH residues, zinc chelation assay in vitro\",\n      \"pmids\": [\"15863623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous genomic targets identified yet\", \"No in vivo binding demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of RRM1 as a direct in vivo transcriptional target via ChIP demonstrated that THAP1 functions as a cell-cycle regulator controlling pRB/E2F target genes and G1/S progression in endothelial cells.\",\n      \"evidence\": \"ChIP, microarray profiling, RNAi, and retroviral overexpression in endothelial cells\",\n      \"pmids\": [\"17003378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors mediating transcriptional regulation were unknown\", \"Whether cell-cycle role extends beyond endothelial cells was untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"NMR structure of the THAP zinc finger revealed its unique fold—an antiparallel β-sheet with a loop-helix-loop insertion—and mapped the DNA-contact surface, providing the structural basis for understanding pathogenic mutations.\",\n      \"evidence\": \"Multidimensional NMR, alanine scanning mutagenesis\",\n      \"pmids\": [\"18073205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of THAP domain bound to DNA\", \"Full-length THAP1 structure not determined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic linkage of THAP1 mutations to DYT6 primary torsion dystonia, combined with demonstration that the causative missense mutation impairs DNA binding, established THAP1 as a dystonia gene and transcriptional dysregulation as a disease mechanism.\",\n      \"evidence\": \"Family-based genetic mapping followed by DNA-binding assay of mutant protein\",\n      \"pmids\": [\"19182804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only one mutation tested functionally\", \"Neural cell-type-specific consequences were unexplored\", \"Whether all DYT6 mutations impair DNA binding was unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two advances resolved THAP1's cofactor recruitment and a disease-relevant target: (1) THAP1 recruits HCF-1 and OGT via a conserved HBM motif to activate RRM1, and (2) THAP1 directly binds and represses the TOR1A promoter, linking two dystonia genes in a common pathway.\",\n      \"evidence\": \"Mass spectrometry, Co-IP, ChIP, RNAi (for HCF-1/OGT); EMSA, ChIP-qPCR, luciferase assays (for TOR1A), replicated across two labs\",\n      \"pmids\": [\"20200153\", \"20976771\", \"20865765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HCF-1 is required at all THAP1 target promoters was unknown\", \"Functional consequence of TOR1A derepression in neurons not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapping of the homodimerization domain to a C-terminal coiled-coil (residues 154–166) established that THAP1 functions as a dimer, while showing that most DYT6 coiled-coil mutations do not disrupt dimerization, pointing to other pathogenic mechanisms.\",\n      \"evidence\": \"Co-IP with domain deletions and systematic mutant analysis\",\n      \"pmids\": [\"21752024\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of dimerization for transcriptional activity was not tested\", \"Single-lab Co-IP without reciprocal pull-down for some mutants\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Biophysical analysis of DYT6 THAP-domain mutations revealed that reduced protein thermostability—not uniformly abolished DNA binding—is a major pathogenic mechanism, with some mutants unfolding below 37°C.\",\n      \"evidence\": \"NMR, DSF, ITC, fluorescence spectroscopy on multiple disease mutants\",\n      \"pmids\": [\"22844099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether reduced stability translates to reduced protein levels in patient neurons was not shown\", \"No in vivo validation of thermostability model\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery of THAP1 autoregulation—binding its own promoter to repress transcription—explained how DYT6 mutations cause elevated THAP1 levels, establishing a negative feedback loop disrupted in disease.\",\n      \"evidence\": \"ChIP, luciferase reporters, RT-qPCR, proteasome inhibitor experiments\",\n      \"pmids\": [\"25088175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Autoregulatory dynamics not measured in neuronal cells\", \"Whether proteasomal degradation of excess THAP1 is a primary clearance mechanism in vivo was not confirmed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Conditional knockout in mouse CNS revealed that THAP1 is essential for oligodendrocyte maturation and myelination timing, acting cell-autonomously to facilitate YY1 DNA occupancy at OL maturation gene promoters—providing the first neural cell-type-specific mechanism for DYT6 dystonia.\",\n      \"evidence\": \"Conditional KO mouse, purified OL progenitor assays, ChIP for YY1\",\n      \"pmids\": [\"28697333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How THAP1 promotes YY1 binding mechanistically was not resolved\", \"Whether myelination defects are the primary cause of dystonia motor phenotype was unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Two new direct THAP1 target pathways were uncovered: (1) GusB regulation controls GAG catabolism in OPCs, with GAG accumulation autoinhibiting maturation (rescuable by β-glucuronidase), and (2) SHLD1 regulation with YY1/HCF1 controls DNA DSB repair pathway choice, conferring PARP inhibitor resistance upon THAP1 loss.\",\n      \"evidence\": \"ChIP, conditional KO rescue with exogenous enzymes/viral overexpression (GusB); ChIP, genetic epistasis, PARP inhibitor sensitivity assays (SHLD1)\",\n      \"pmids\": [\"34312226\", \"33857404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SHLD1 dysregulation contributes to dystonia pathology is unknown\", \"GAG catabolism pathway not validated in human OPCs\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The DYT6 F81L knockin mouse showed that this mutation does not abolish THAP1 DNA binding but instead prevents YY1 recruitment, establishing that failure to organize an active transcription complex—not loss of DNA binding per se—is a distinct pathogenic mechanism.\",\n      \"evidence\": \"Knockin mouse, ChIP for THAP1 and YY1, myelination assays\",\n      \"pmids\": [\"34686877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how F81L disrupts YY1 recruitment is unknown\", \"Whether this mechanism applies to other THAP domain mutations is untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Epigenomic profiling across patient cortex, iPSC-neurons, and KO models revealed that THAP1 directly targets only a minority of dysregulated genes; broader transcriptional effects are mediated indirectly through SP1 and SP4, expanding the model from direct target regulation to a hierarchical transcription factor network.\",\n      \"evidence\": \"ChIP-seq and RNA-seq across patient tissue, iPSC-derived neurons, rat KO, and cell lines\",\n      \"pmids\": [\"35015830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SP1/SP4 regulation by THAP1 not shown to be direct at all loci\", \"Cell-type specificity of indirect effects not fully delineated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"THAP1 was identified as a direct transcriptional regulator of PSMB5, and its loss causes defective proteasome assembly and impaired proteostasis—establishing proteasome homeostasis as a fundamental THAP1-dependent process, validated by deep mutational scanning of the entire protein.\",\n      \"evidence\": \"Genome-wide genetic screen, ChIP, proteasome activity assays, deep mutational scanning, PSMB5 rescue, replicated across two independent studies\",\n      \"pmids\": [\"39952963\", \"39929834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether proteostasis defects contribute to DYT6 neuronal dysfunction is unknown\", \"Relative importance of PSMB5 versus other targets in disease not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"THAP1 was discovered to function as a maternal-effect factor activating Rrm1 in oocytes; its loss causes zygotic genome activation failure and 1–2-cell arrest, rescuable by Rrm1 overexpression, revealing an unexpected role in the earliest stages of embryonic development.\",\n      \"evidence\": \"Oocyte-specific conditional KO, ZGA assays, low-input metabolomics, Rrm1 rescue\",\n      \"pmids\": [\"41731150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether THAP1 maternal function is relevant to human fertility is unknown\", \"Full set of THAP1 maternal targets beyond Rrm1 not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of THAP1-mediated YY1 and HCF-1 co-recruitment, the relative contribution of myelination versus neuronal transcriptional defects to DYT6 dystonia, and whether proteasome homeostasis dysfunction is a primary driver of disease pathology.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal or cryo-EM structure of THAP1 with any partner or DNA\", \"Causal hierarchy among THAP1 target pathways in dystonia neurons not established\", \"Full-length THAP1 structure including coiled-coil domain not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 3, 5, 8, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 6, 9, 11, 13, 14, 17, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 20, 21, 22]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 5, 6, 9, 14, 16, 17, 23]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 13]}\n    ],\n    \"complexes\": [\n      \"THAP1 homodimer\",\n      \"THAP1–HCF-1–OGT complex\",\n      \"THAP1–Par-4 complex\"\n    ],\n    \"partners\": [\n      \"HCF1\",\n      \"OGT\",\n      \"PAWR\",\n      \"YY1\",\n      \"SP1\",\n      \"SP4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}